Resiquimod and polyinosinic–polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine by Chun-Xue Zhou et al.
Zhou et al. BMC Veterinary Research 2014, 10:2
http://www.biomedcentral.com/1746-6148/10/2RESEARCH ARTICLE Open AccessResiquimod and polyinosinic–polycytidylic acid
formulation with aluminum hydroxide as an
adjuvant for foot-and-mouth disease vaccine
Chun-Xue Zhou, Dong Li*, Ying-Li Chen, Zeng-Jun Lu, Pu Sun, Yi-Mei Cao, Hui-Fang Bao, Yuan-Fang Fu,
Ping-Hua Li, Xing-Wen Bai, Bao-Xia Xie and Zai-Xin Liu*Abstract
Background: Toll-like receptor (TLR) agonists reportedly have potent antiviral and antitumor activities and may be a new
kind of adjuvant for enhancing immune efficacy. Resiquimod (R848) is an imidazoquinoline compound with potent
antiviral activity and functions through the TLR7/TLR8 MyD88-dependent signaling pathway. Polyinosinic-polycytidylic acid
[poly(I:C)] is a synthetic analog of double-stranded RNA that induces the production of pro-inflammatory cytokines by the
activation of NF-κB through TLR3. This study investigated the potential of R848 and poly(I:C) as an adjuvant 146S
foot-and-mouth disease virus (FMDV) vaccine formulated with aluminum hydroxide (Al(OH)3).
Results: Antibody titers to FMDV and CD8+ T cells were markedly enhanced in mice immunized to
146S FMDV + Al(OH)3 + R848 + poly(I:C) compared with mice immunized to FMDV + ISA206. IFN-γ secretion
substantially increased compared with IL-4 secretion by splenic T cells stimulated with FMDV antigens in vitro,
suggesting that R848, poly(I:C), and with Al(OH)3 together biased the immune response toward a Th1-type
direction.
Conclusions: These results indicated that the R848 and poly(I:C) together with Al(OH)3 enhanced humoral
and cellular immune responses to immunization with 146S FMDV antigens. Thus, this new vaccine formulation
can be used for FMDV prevention.
Keywords: R848, Poly(I:C), Aluminum hydroxide, FMDVBackground
Foot-and-mouth disease virus (FMDV), which belongs to
family Picornaviridae, genus Aphthovirus, causes a highly
contagious and devastating disease in cloven-hoofed ani-
mals, such as cattle, swine, sheep, and goats [1]. FMDV was
first discovered by Loeffler and Frosch in the late nine-
teenth century [2]. Since then, outbreaks of foot-and-
mouth disease (FMD) in Asia and Europe have led to the
slaughter of millions of infected animals and billions of dol-
lar loss [3,4].
FMD, which has been reported in many areas of the
world, has the features of fever, short-lived viremia, and le-
sions on feet and tongue. The disease can be controlled by* Correspondence: lidong@caas.cn; liuzaixin@caas.cn
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reproduction in any medium, provided the orvaccination of chemically inactivated whole virus formu-
lated with adjuvant. Aluminum salts are the only ones li-
censed in human vaccines and mainly enhances Th2-
specific immune responses. Extensive clinical data have
demonstrated that aluminum salt vaccines have excellent
safety profiles and limited adverse reactions in injection
sites. Both aluminum hydroxide (Al(OH)3) adjuvant and
mineral oil adjuvant have been applied to control FMD.
However, the antibody titers were higher and the morbidity
rates were lower in cattle, sheep, and pigs when emulsified
oil is used as an adjuvant [5]. Moreover, the ability of the
aluminum adjuvant to enhance Th1 cell-mediate immune
responses is insufficient. However, mineral oil adjuvant can
induce local and general reactions, such as granuloma, gan-
grene, or fever [6].
Toll-like receptors (TLRs) are pattern recognition recep-
tors that play an important role in innate immune response.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells (DCs), and macrophages [7]. The engagement of TLRs
in DCs links innate immunity and adaptive immunity,
which is vital for immune cell maturation, cell differenti-
ation (Th1/Th2) based on pro-inflammatory cytokines, and
proliferation of antigen-specific CD4+ and CD8+T cells [8].
To date, 13 TLRs have been confirmed in both humans
and mice. Many natural or synthetic ligands that recognize
the TLRs have also been discovered [9]. TLR7, which favors
a TH1 response, can be activated by some synthetic ago-
nists, such as imiquimod [10,11], resiquimod (R848)
[12,13], and 3 M-052 [14]. Imiquimod and R848 have been
demonstrated to have immune response properties in terms
of antiviral and antitumor activities. Imiquimod, the first
synthetic imidazoquinoline, is approved for the topical
treatment of genital warts, skin cancer, superficial basal cell
carcinoma, and actinic keratosis [15]. Through conven-
tional subcutaneous and intramuscular vaccination, R848
shows that these molecules could enhance DCs maturation,
as well as cellular and humoral adaptive immunities in
mice, rats, guinea pigs, and monkeys [16].
Polvriboinsine–polyribocyaidylic acid [poly(I:C)] is a
synthetic analog of double-stranded RNA that could
recognize TLR3 and lead to the activation of NF-κB and
the secretion of pro-inflammatory cytokines. Poly(I:C)
has been shown to induce the production of IL-12 and
IFN-γ, which could shift the Th2-type response to Th1-
type response.
Thus far, ISA206 is considered the most effective oil
adjuvant in FMD vaccines for protecting animals against
infection. To determine if other types of adjuvants are
more effective than ISA206, this study was carried out
to determine the ability of R848 and poly(I:C) in assist-
ing Al(OH)3 as FMD vaccine.
Methods
Reagents and virus
R848 and poly(I:C) were manufactured by Sigma–
Aldrich (St. Louis, MO, USA). ISA206 was purchased
from Seppic Company (France). Al(OH)3 (pH 7.4) was
prepared in our laboratory and stored at 4°C.
The FMDV strain used was a type-O FMDV vaccine
strain isolated and stored in our laboratory. The procedures
for virus preparation were performed as previously de-
scribed [17]. This strain was propagated in a BHK-21 cell
line and inactivated using binary ethyleneimine for 24 h at
37°C. Then, 146S antigen was concentrated and purified by
sucrose density gradient centrifugation. In a typical proced-
ure, appropriately inactivated virus samples were centri-
fuged through a cushion of 20% sucrose in TNE buffer
[containing 10 mM Tris–HCl (pH 7.5), 0.1 M NaCl, and
1 mM EDTA] in an AH-625 rotor (Sorvall) at 25 000 rpm,
2.5 h, and 4°C. The viral pellet was resuspended in TNE
and centrifuged in 25%-45% (w/w) sucrose densitygradients in the same buffer at 37 000 rpm, 1 h, and 4°C in
a SW40 rotor (Beckman). After centrifugation, the gradi-
ents were scanned at 254 nm using UA-5 or UA-6 absorb-
ance detectors. To prepare the whole virus particle
standard, sucrose was removed by ultrafiltration using Cen-
tricon Plus-70 filter devices with Amicon Ultracel PL-30
membranes (Millipore, USA) following instructions from
the manufacturer.
Animals
Female BALB/c mice (purchased from Lanzhou University,
China), approximately 5 weeks to 8 weeks old, were used in
this study. They were acclimated for a week before studies
begun, i.e., maintained in standard mouse chow and condi-
tions in an animal facility. All mice were weighed prior to
initiation to provide a baseline for detecting the systemic
toxicity of treatments that could cause weight loss. The
State Key Laboratory of Veterinary Etiological Biology and
Key Laboratory of Animal Virology of the Ministry of Agri-
culture approved all protocols using animals (permission
number: CNAS-BL0012.date:2011.11-2016.11).
Immunization protocols
Mice in six groups (twelve mice each) were intramuscu-
larly (IM) injected once in posterior limbs with one of the
following formulations: (1) 146S + ISA206 (F + 206), (2)
146S + Al(OH)3 (F + A), (3) 146S + Al(OH)3 + 20 μg
poly(I:C) (F + A + P), (4) 146S +Al(OH)3 + 20 μg R848
(F + A + R), (5) 146S + Al(OH)3 + 20 μg poly(I:C) +
20 μg R848 (F + A + P + R), and (6) placebo (PBS).
146S FMDV was administrated at 2.0 μg per mouse. All
tested mice were bled before immunization (day 0) and
then immunized. Blood samples were obtained at 3, 7, 14,
21, 28, and 35 days post-vaccination (dpv). Sera were sepa-
rated by centrifugation at 4000 rpm for 10 min and stored
at−20°C until antibody titers were tested.
Determination of FMDV type O specific antibody titers
To measure FMDV type O-specific antibody titers fol-
lowing immunization, blood was obtained from each
mouse. ELISA was performed according to the specifica-
tions in an LPB-ELISA commercial kit (LVRI, China). In
a typical procedure, the ELISA plates were coated with
rabbit antiserum against FMDV type O overnight at
room temperature. Serum sample dilutions (from 1:4 to
1:512) were incubated overnight at 4°C at a pre-titrated
dose of the corresponding virus strain (FMDV O type in
this study) in a saline buffer liquid phase. The next day,
the mixtures in the serum dilution plate were transferred
into the ELISA plate and incubated for 1 h at 37°C. After
a washing step (total of five times with PBST), a second
incubation was carried out with guinea pig antiserum
against FMDV O type for 1 h at 37°C. After a wash step
similar to the one above, 50 μL of prepared rabbit anti-
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then covered with a plate sealer and incubated for 1 h at
37°C. Then, 50 μL of the substrate/chromophore mix-
ture (H2O2/OPD) was added to each well, and the plate
(without plate sealer) was incubated for 15 min at room
temperature in the dark. Finally, 50 μL of stop solution
was added to each well, and absorbance at 492 nm was
read within 15 min of stopping the reaction.Preparation of splenic lymphocytes
Individual spleens were cut into small pieces with scis-
sors. Single cell suspension was prepared by gently
squeezing through a 70 μm cell strainer. Leukocytes
were isolated by density gradient centrifugation for
20 min at 1000 × g using Ez-Sep Mouse 1 × lymphocyte
separation medium (Dakewe, China). The portion of the
medium containing lymphocyte was transferred into a
new tube and then washed with RPMI 1640. Cells were
isolated by density gradient centrifugation for 10 min at
450 × g, and the supernatant was discarded. Finally, cells
were resuspended in RPMI 1640 (containing penicillin/
streptomycin) supplemented with 5% FCS at 5 × 106
cells/mL and stored at 4°C.Detection of IFN-γ/IL-4
About 5 × 105 spleen lymphocytes were added to each
well of a 96-well microtiter plate at a final volume of
100 μL. Cells from each spleen or pools of spleens were
added to each of 9 wells, 3 for PBS control, 3 for PHA
control (10 μg/mL; Sigma), and 3 for 2 μg/ml of specific
antigen (146S FMDV) challenge. The cells were then in-
cubated for 48 h at 37°C in a humidified atmosphere of
5.0% CO2 in air. The plates were then centrifuged for
10 min at 4000 rpm to settle cells to the well bottom,Figure 1 In vitro immune activation of BALB/c mice splenocytes by R
incubated with 0.01, 0.1, 1, 10, 20, 40, and 100 μg/ml R-848 or 0.01, 0.1, 1, 1
48 h after stimulation and assayed for TNFα, IFN-γ, and IL-4 using ELISA. Thand the medium was removed for analysis of IFN-γ and
IL-4 production by ELISA (BD Company, USA).
Detection of CD3+CD4+T and CD3+CD8+T cells
For CD3+CD4+ and CD3+CD8+T cell staining, total spleen
lymphocytes from immunized mice were isolated and
stained with anti-CD3-ALEXA FLUOR®488 & anti-CD4-
ALEXA FLUOR®647 or anti-CD3-ALEXA FLUOR®488 &
anti-CD8-ALEXA FLUOR®647(BD Phamingen, USA) in
darkness for 20 min. Cells were isolated by density gradient
centrifugation for 10 min at 3000 rpm. After discarding the
supernatant, cells were twice washed with PBS and resus-
pended in 0.5 mL of PBS. The cells were then analyzed with
a FACSAria (BD) within 4 h.
Statistical analyses
The statistical significance of the differences in the means
of experimental groups was determined by one- or two-
way ANOVA analysis. Results are expressed as the mean ±
standard error of mean. A difference was deemed statisti-
cally significant if p < 0.05.
Results
Effects of R848 and poly(I:C) on naïve splenocytes in vitro
Naïve BALB/c splenocytes were prepared and stimulated
with either R848 (0.01, 0.1, 1, 10, 20, 40, 100 μg/mL) or
poly(I:C) (0.01, 0.1, 1, 10, 20, 40, and 100 μg/mL). ConA
(Sigma Chemical Company, USA) were used as positive
control, and PBS was used as negative control (Figure 1).
Splenocytes were cultured for 48 h, and cytokine induc-
tion was measured by harvesting splenocyte superna-
tants. To investigate the effect of R848 and poly(I:C) on
the changes in Th1 and Th2 immune response in vitro,
splenocyte supernatants were measured with a commer-
cially available kit (BD company, USA). When tested for848 and poly(I:C). Naїve BALB/c mice splenocytes (106/ml) were
0, 20, 40, and 100 μg/ml poly(I:C). Culture supernatants were obtained
e results shown are representatives of three independent experiments.
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cytokines, both R848 and poly(I:C) induced the highest
levels of TNF and IFNγ (Th1 cytokine) at 20 μg/mL.
R848 appeared to be superior to poly(I:C) in inducing
TNF and IFNγ. However, R848 and poly(I:C) induced
the lowest levels of IL-4 (Th2 cytokine) when they were
administered at 20 μg/mL. Results revealed that both
R848 and poly(I:C) regulated the production of selective
Th1 or Th2 cytokines, which favor a Th1 bias [18].Antibody response
Humoral immune responses were analyzed by screening
for serum IgG using liquid-blocking ELISA specific for
FMDV type O. Sera were collected prior to immunization
and at different days after the immunization. The levels of
anti-FMDV type O IgG at different days following
immunization to FMDV formulated with different materials
are shown in Figure 2. Pre-immune sera (day 0) were de-
tected and found negative for anti-FMDV antibodies.
Immunization to FMDV formulated with alum and R848
induced a weaker IgG antibody response than the F +A
group. When mice were immunized with FMDV formu-
lated with alum and poly(I:C), the obtained antibody titers
were higher and almost equivalent to that in the F +A
group. However, immunization to FMDV formulated with
alum, R848, and poly(I:C) induced a striking, fourfold
higher antibody, even higher than that in the F + 206 group
at 14 and 21 dpv (p < 0.05). All above results showed that
the combination of R848 and poly(I:C) played an important
role in boosting anti-FMDV antibodies.Stimulation of immunized mice splenocytes in vitro
R848 and poly(I:C) as adjuvant reportedly induce a substan-
tial increase in both Th1- and Th2-type immune responsesFigure 2 Enhancement of anti-FMDV IgG antibody by the immunizati
bled at different dpv’s. Sera from three mice were pooled together within
using ELISA. One asterisk indicates that p < 0.05 when comparing results fro
PBS group. Two asterisks indicate p < 0.05 when comparing results from th
group. Each bar represents the mean antibody titer ± standard error of 12 m[19,20]. To determine the potential functions of R848 and
poly(I:C) accompanied with FMDV antigens in Th1/Th2-
type immune response, cytokine levels were assayed. As
shown in Figure 3, R848 and poly(I:C) promoted IFN-γ
production. In the F +A+R + P group, the level of IFN-γ
was fivefold higher than that in the F +A group and a little
lower than that in the F + 206 group (p > 0.05). However,
no significant difference was observed in IL-4 production
between the F +A+R + P and F + 206 groups (p > 0.05), in-
dicating that R848 and poly(I:C) biased the immune
response toward a Th1-type direction.Flow cytometry analysis
To characterize the cell-mediated immune responses,
BALB/C mice were sacrificed and a single splenocyte
suspension was prepared at 21 dpv. The T cell anti-
gen receptor-CD3 complex plays an important role in
the recognition and response to antigens. CD4 and
CD8 are T cell surface glycoproteins that recognize
major histocompatibility complex (MHC) antigens
and play a critical role in signal transduction and T
cell activation [21]. When CD3+CD4+ cells were eval-
uated post-vaccination, the F + A group remained un-
changed relative to the PBS group, and the other
groups had higher percentages of this cells than the
PBS group. However, no significant difference was ob-
served between the F + 206 and F + A + P + R groups
(p > 0.05) (Figure 4a). The percentage of CD3+CD8+ T
cells was also evaluated, except for the F + A group,
relative to the PBS group. However, when using the
same specific antigens, the ability to stimulate CD8 T
cell proliferation through different immune formula-
tion was better in the F + A + R, F + A + P, and espe-
cially in the F + A + R + P groups (Figure 4b).on of FMDV antigens together with R848 and poly(I:C). Mice were
the same group, and total IgG anti-FMDV antibody titers were detected
m the ISA206, F + A, F + A + P, F + A + R, or F + A + P + R groups to the
e ISA206, F + A + P, F + A + R, or F + A + P + R groups with the F + A
ice per group.
Figure 3 Induction of IFN-γ and IL-4 by the immunized mice splenocytes. Mice were sacrificed at 35 dpv. Spleens were isolated and ground
into single cells under sterile conditions. Single spleen lymphocyte suspensions (5 × 106 /ml) were obtained using commercial EZ-SepTM Mouse
1× Lymphocyte Separation Medium. About 200 μl of cells was stimulated by FMDV antigens as specific antigen, PHA as positive control, and PBS
as negative control .One asterisk indicates that p < 0.05 when comparing results from the ISA206, F + A, F + A + P, F + A + R, F + A + P + R, or PHA
groups to the PBS group. Two asterisks indicate p < 0.05 when comparing results from the F + A, F + A + P, F + A + R, or F + A + P + R to ISA206
groups. Data are shown as the mean ± standard error of 12 mice per group.
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The important finding of this study was that R848, poly
(I:C), and Al(OH)3 enhanced the immune response
against the FMDV, which has not yet been reported.
The immunization of FMDV formulated with R848, poly
(I:C), and Al(OH)3 markedly augmented antibody and
cellular immune responses. However, weak humoral and
cellular responses were elicited by FMDV and Al(OH)3
immune formulation.
The immunomodulatory effects of imidazoquinolines
have been extensively studied both in mice and humans.
Imiquimod, the first synthetic imidazoquinoline, is ap-
proved by the FDA for the topical treatment of viruses,
such as human papillomavirus and genital HSV-2. R848,
another imidazoquinoline, has been shown to preferen-
tially enhance Th1 immune response through the recog-
nition of TLR7 in antigen-presenting cells in mice,
especially DCs [22]. Their binding induced the activation
of DCs and the production of Th1-biased cytokines,
such as TNF-α, IL-12, and IFN-γ. Immune responseFigure 4 Effect induced by FMDV with different chemicals on T lymph
CD3+CD8+ subsets were assessed by two-color flow cytometry analysis. (a)
cells from immunized mouse spleen. One asterisk indicates that p < 0.05 w
A + P + R, or PHA groups to the PBS group. Two asterisks indicate p < 0.05
P + R groups to the ISA206 group. All experiments were obtained in triplica
from three independent experiments are shown.against FMDV in natural hosts is probably T-cell
dependent, and cell-mediated immunity may be involved
in the clearance of persistent FMDV [23]. Ideally, a
FMDV vaccine should be able to prime Th1/Th2-bal-
anced immune responses to eliminate FMDV infection.
The Th1 cytokines induced in vaccinated animals were
correlated with the ability to control viral replication.
The expression of IL-12 and IFN-γ in immune cells
responding to the FMDV reflects a dominance of Th1
type cells that can contribute to virus clearance. In gen-
eral, Th1 cells are better endowed than Th2 to deal with
viral infections [24].
Poly(I:C) could increase Th1 cytokines and type I IFNs
by activating innate immunity through TLR3 and some
other molecules mediating signal transduction. Then,
DC maturation and B cell activation are induced [25].
Potent CD4+ T cell and humoral immune responses can
thus be induced. Moreover, both R848 and poly(I:C)
could generate CD8+ T cell immune response through
different mechanisms [26,27]. Collectively, these dataocyte subsets of mouse spleen. The proportions of CD3+CD4+ and
CD3+CD4+ T cells from immunized mouse spleen. (b) CD3+CD8 +T
hen comparing results from the ISA206, F + A, F + A + P, F + A + R, F +
when comparing results from the F + A, F + A + P, F + A + R, or F + A +
te, and data shown are the mean ± standard error. Representatives
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munomodulators for improving humoral and cellular
immune responses.
Pure FMDV protein antigens have poor immunogen-
icity, which is the main cause of low immune efficacy in
FMDV control and prevention. Using adjuvants can im-
prove immunotherapy or vaccines. However, adjuvants
used in FMD vaccines are salts of aluminum and min-
eral oil. Salts of aluminum have good safety record but
produce poor T cell responses, and mineral oil produces
high Th1 cell response but causes severe local toxicity.
As part of the present study, the co-delivery of these ma-
terials accompanying FMDV must not induce severe
local and general toxicity. Fortunately, observations of
mice body weight, diurnal thermal variation of body
temperature, animal behaviors, and pathological changes
at the injection sites revealed that these materials were
completely safe for use (data not shown).
Adjuvants such as alum or ISA206 alone can promote
strong antibody responses. However, when added with
R848 and poly(I:C), the antibody titers induced by
FMDV were even higher than that in the F + A or F +
206 groups at 14 dpv, which indicated that R848 and
poly(I:C) may be important for humoral response
regulation.
In vitro analyses of the effects of R848 and poly(I:C) on
immune cells showed that they induced the up-regulation
of IFN-γ production and down-regulation of IL-4, which
meant that R848 and poly(I:C) shifted the immune re-
sponses caused by FMDV and Al(OH)3 toward a Th1 direc-
tion. In vivo, R848 and poly(I:C) markedly affected the
subpopulation of T lymphocyte cells, which enhanced both
the percentages of CD4+ and CD8+ T cells when the two
TLR agonists were administered together. Therefore, the
two immunoregulatory materials could work together to
improve the cellular responses induced by FMDV antigens
formulated with alum.
Conclusions
The study provided substantial evidence of the use of
R848 and poly(I:C) as TRL agonists for FMDV alum vac-
cines in a mice model. Particular application was dem-
onstrated for inducing a high amount of IgG antibody
and Th1-biased immune responses. The findings can
serve as a foundation for further studies on these TLR
agonists for FMDV protein vaccination in large animals.
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